Learn more about the healthcare and biotechnology startup companies powered by technology developed at Mount Sinai.
Biopharmaceutical company advancing the development of small molecule therapeutics for the treatment of neurodegenerative and renal disorders, including Parkinson’s disease and kidney disease.
Digital therapeutics company that develops, validates, and commercializes software as prescription medical treatments for a variety of conditions. The Emotional Faces Memory Task (EFMT) technology used in the company’s digital therapeutic to treat major depressive disorder, known as CT-152, was originally developed by Mount Sinai researchers. Click has partnered with Otsuka Pharmaceutical Development & Commercialization, Inc. for the development and distribution of the novel treatment, and a first-of-its-kind, fully remote clinical trial is currently underway to validate the treatment in support of FDA authorization.
Acute-care services company that is utilizing Mount Sinai’s Hospitalization at Home and Palliative Care at Home programs to expand outpatient, ambulatory and home-based care capabilities.
Based on underlying technology developed at Mount Sinai, Kantaro is a joint venture between Mount Sinai and Renalytix to develop and scale production of rigorous, results-driven and reproducible diagnostic and serology tests for critical health challenges, with an initial focus on COVID-19. Kantaro was granted emergency use authorization by the FDA in April 2020. Kantaro was named to Fast Company’s World’s Most Innovative Companies 2021 list, ranking first in the Joint Venture category, and was a finalist for the World’s Changing Ideas in the Pandemic Response category.
A patient-centric precision exposome medicine company, Linus Biotechnology’s molecular phenotyping platform is being utilized to develop biomarkers outside the scope of genomics that operate across multiple disease domains, including the central nervous system (autism spectrum disorder and amyotrophic lateral sclerosis), gastroenterology (inflammatory bowel disease), renal disease and oncology.
Monogram Orthopedics is developing 3D printed custom implants for patients and a state-of-the-art robot that prepares the bones into which the implants are inserted for less invasive and more precise joint reconstruction surgery. Monogram participated in MSIP’s i3 Accelerator, closed on an over $14 million funding round in 2020, raised $8.3 million in 2021 to date, and has valuation of nearly $90 million.
An augmented intelligence healthcare services provider delivering patient-specific insights that aid in disease state characterization and enable better treatment decisions and outcomes.
Diagnostics company (NASDAQ: RNLX, market cap: over $950M) powered by KidneyIntelX, a prognostic test developed in conjunction with Mount Sinai that identifies individuals who will rapidly progress towards kidney failure. KidneyIntelX allows clinicians to assess the risk of progressive kidney function decline in patients in type 2 diabetes and early-stage chronic kidney disease to optimize their care and promote better outcomes.
Enterprise-grade digital health platform enabling evidence-based automated care plans to be prescribed via electronic health records and care management systems.
A patient-centered health intelligence company advancing healthcare through data-driven insights. As a Mount Sinai spinout, Sema4 applies AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Sema4 began trading on the NASDAQ Global Market in July 2021 with a $3 billion valuation and completed a Series C funding round of $121 million in August 2020.
Trellus Health is a connected health solution for complex, chronic conditions that addresses physical and behavioral health. Through its resilience-driven methodology, Trellus utilizes clinical expertise and multidisciplinary methods to connect patients and caregivers with experts, coaches, tools, and resources for a total care approach. The first-of-its-kind startup secured $5 million in seed funding in 2020 and was listed on the London Stock Exchange’s Alternative Investment Market (AIM) for small to medium growth companies in May 2021.
Verici Dx is developing advanced clinical diagnostics to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. Verici Dx’s two leading commercial clinical offerings, Clarava™ and Tuteva™, were developed at Mount Sinai.